Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH): Multiple Studies on Golidocitinib and Birelentinib Selected for 67th ASH Annual Meeting

Stock News11-04

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH) announced that it will present multiple latest research findings on its two core products in lymphoma treatment—Golidocitinib (generic name: Golidocitinib Capsules) and Birelentinib (DZD8586)—at the 67th American Society of Hematology (ASH) Annual Meeting from December 6 to 9. A total of 15 abstracts from the company were selected for the conference, demonstrating its robust pipeline and R&D potential in hematologic malignancies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1159498388?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 17:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159498388","market":"us","top_or_hot":-1,"title":"Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH): Multiple Studies on Golidocitinib and Birelentinib Selected for 67th ASH Annual Meeting","media":"Stock News","content":"<p>Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH) announced that it will present multiple latest research findings on its two core products in lymphoma treatment—Golidocitinib (generic name: Golidocitinib Capsules) and Birelentinib (DZD8586)—at the 67th American Society of Hematology (ASH) Annual Meeting from December 6 to 9. A total of 15 abstracts from the company were selected for the conference, demonstrating its robust pipeline and R&D potential in hematologic malignancies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH): Multiple Studies on Golidocitinib and Birelentinib Selected for 67th ASH Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH): Multiple Studies on Golidocitinib and Birelentinib Selected for 67th ASH Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-04 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH) announced that it will present multiple latest research findings on its two core products in lymphoma treatment—Golidocitinib (generic name: Golidocitinib Capsules) and Birelentinib (DZD8586)—at the 67th American Society of Hematology (ASH) Annual Meeting from December 6 to 9. A total of 15 abstracts from the company were selected for the conference, demonstrating its robust pipeline and R&D potential in hematologic malignancies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4109","symbol_name":"特种化学制品","start_time":0,"source_url":"","article_id":"1159498388","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159498388","pubTimestamp":1762247771,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH) announced that it will present multiple latest research findings on its two core products in lymphoma treatment—Golidocitinib (generic name:...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688192":"迪哲医药","BK4109":"特种化学制品","BK0239":"医药制造","ASH":"Ashland","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC"},"translate_title":"迪扎尔（江苏）药业股份有限公司（688192.SH）：Golidocitinib和Birelentinib多项研究入选第67届ASH年会","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688192":1,"ASH":1},"content_text":"Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH) announced that it will present multiple latest research findings on its two core products in lymphoma treatment—Golidocitinib (generic name: Golidocitinib Capsules) and Birelentinib (DZD8586)—at the 67th American Society of Hematology (ASH) Annual Meeting from December 6 to 9. A total of 15 abstracts from the company were selected for the conference, demonstrating its robust pipeline and R&D potential in hematologic malignancies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1159498388","isCrawlerRequest":true}